344 related articles for article (PubMed ID: 35053194)
1. The Diagnostic and Therapeutic Potential of Galectin-3 in Cardiovascular Diseases.
Sygitowicz G; Maciejak-Jastrzębska A; Sitkiewicz D
Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053194
[TBL] [Abstract][Full Text] [Related]
2. The role of galectin-3 in heart failure and cardiovascular disease.
Zhong X; Qian X; Chen G; Song X
Clin Exp Pharmacol Physiol; 2019 Mar; 46(3):197-203. PubMed ID: 30372548
[TBL] [Abstract][Full Text] [Related]
3. [Galectin 3--a new biomarker for diagnostics and outcome of chronic heart failure].
Lakomkin SV; Skvortsov AA; Goriunova TV; Masenko VP; Tereshchenko SN
Kardiologiia; 2012; 52(3):45-52. PubMed ID: 22839443
[TBL] [Abstract][Full Text] [Related]
4. The Role of Galectin-3 in Heart Failure-The Diagnostic, Prognostic and Therapeutic Potential-Where Do We Stand?
Zaborska B; Sikora-Frąc M; Smarż K; Pilichowska-Paszkiet E; Budaj A; Sitkiewicz D; Sygitowicz G
Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37685918
[TBL] [Abstract][Full Text] [Related]
5. Galectin-3 in heart failure pathology--"another brick in the wall"?
Lala RI; Puschita M; Darabantiu D; Pilat L
Acta Cardiol; 2015 Jun; 70(3):323-31. PubMed ID: 26226706
[TBL] [Abstract][Full Text] [Related]
6. Review of the prognostic value of galectin-3 in heart failure focusing on clinical utility of repeated testing.
Carrasco-Sánchez FJ; Páez-Rubio MI
Mol Diagn Ther; 2014 Dec; 18(6):599-604. PubMed ID: 24989720
[TBL] [Abstract][Full Text] [Related]
7. Galectin-3: a new biomarker for the diagnosis, analysis and prognosis of acute and chronic heart failure.
Hrynchyshyn N; Jourdain P; Desnos M; Diebold B; Funck F
Arch Cardiovasc Dis; 2013 Oct; 106(10):541-6. PubMed ID: 24090952
[TBL] [Abstract][Full Text] [Related]
8. Role of oxidative stress-related biomarkers in heart failure: galectin 3, α1-antitrypsin and LOX-1: new therapeutic perspective?
Lubrano V; Balzan S
Mol Cell Biochem; 2020 Jan; 464(1-2):143-152. PubMed ID: 31782085
[TBL] [Abstract][Full Text] [Related]
9. Galectin-3: A Potential Prognostic and Diagnostic Marker for Heart Disease and Detection of Early Stage Pathology.
Hara A; Niwa M; Kanayama T; Noguchi K; Niwa A; Matsuo M; Kuroda T; Hatano Y; Okada H; Tomita H
Biomolecules; 2020 Sep; 10(9):. PubMed ID: 32899694
[TBL] [Abstract][Full Text] [Related]
10. Galectin-3 and heart failure: prognosis, prediction & clinical utility.
Filipe MD; Meijers WC; Rogier van der Velde A; de Boer RA
Clin Chim Acta; 2015 Mar; 443():48-56. PubMed ID: 25446877
[TBL] [Abstract][Full Text] [Related]
11. Galectin-3 and post-myocardial infarction cardiac remodeling.
Meijers WC; van der Velde AR; Pascual-Figal DA; de Boer RA
Eur J Pharmacol; 2015 Sep; 763(Pt A):115-21. PubMed ID: 26101067
[TBL] [Abstract][Full Text] [Related]
12. Predictive value of galectin-3 for incident cardiovascular disease and heart failure in the population-based FINRISK 1997 cohort.
Jagodzinski A; Havulinna AS; Appelbaum S; Zeller T; Jousilahti P; Skytte-Johanssen S; Hughes MF; Blankenberg S; Salomaa V
Int J Cardiol; 2015 Aug; 192():33-9. PubMed ID: 25985013
[TBL] [Abstract][Full Text] [Related]
13. Using galectin-3 to reduce heart failure rehospitalization.
Xue Y; Maisel A; Peacock WF
Future Cardiol; 2014 Mar; 10(2):221-7. PubMed ID: 24762249
[TBL] [Abstract][Full Text] [Related]
14. Plasma and Cardiac Galectin-3 in Patients With Heart Failure Reflects Both Inflammation and Fibrosis: Implications for Its Use as a Biomarker.
Besler C; Lang D; Urban D; Rommel KP; von Roeder M; Fengler K; Blazek S; Kandolf R; Klingel K; Thiele H; Linke A; Schuler G; Adams V; Lurz P
Circ Heart Fail; 2017 Mar; 10(3):. PubMed ID: 28288987
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of galectin-3 in patients with heart failure.
Bošnjak I; Selthofer-Relatić K; Včev A
Dis Markers; 2015; 2015():690205. PubMed ID: 25960597
[TBL] [Abstract][Full Text] [Related]
16. Galectin-3 in Heart Failure: An Update of the Last 3 Years.
Gehlken C; Suthahar N; Meijers WC; de Boer RA
Heart Fail Clin; 2018 Jan; 14(1):75-92. PubMed ID: 29153203
[TBL] [Abstract][Full Text] [Related]
17. [Impact of galectin 3 as myofibrosis marker in clinical cardiology].
Málek F
Vnitr Lek; 2014 Apr; 60(4):327-30. PubMed ID: 24985993
[TBL] [Abstract][Full Text] [Related]
18. Modified citrus pectin ameliorates myocardial fibrosis and inflammation via suppressing galectin-3 and TLR4/MyD88/NF-κB signaling pathway.
Xu GR; Zhang C; Yang HX; Sun JH; Zhang Y; Yao TT; Li Y; Ruan L; An R; Li AY
Biomed Pharmacother; 2020 Jun; 126():110071. PubMed ID: 32172066
[TBL] [Abstract][Full Text] [Related]
19. Usefulness of a combination of monocyte chemoattractant protein-1, galectin-3, and N-terminal probrain natriuretic peptide to predict cardiovascular events in patients with coronary artery disease.
Tuñón J; Blanco-Colio L; Cristóbal C; Tarín N; Higueras J; Huelmos A; Alonso J; Egido J; Asensio D; Lorenzo Ó; Mahíllo-Fernández I; Rodríguez-Artalejo F; Farré J; Martín-Ventura JL; López-Bescós L
Am J Cardiol; 2014 Feb; 113(3):434-40. PubMed ID: 24295549
[TBL] [Abstract][Full Text] [Related]
20. Galectin-3 in patients with coronary heart disease and atrial fibrillation.
Kang Q; Li X; Yang M; Fernando T; Wan Z
Clin Chim Acta; 2018 Mar; 478():166-170. PubMed ID: 29287900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
